Moderna, Inc.Long
Vaccine Stock Mania pushes Moderna to a $29bn Market Cap
- On Monday there was news that Moderna’s Covid-19 vaccine candidate is generating an immune response in Phase 1 trial subjects.
- We also then saw massive buying push the market cap to now $29 billion. This is NOT a proven company and doesn't have any marketable product YET.
- Some concern has since been expressed by Vaccine experts others on on when company will release full data / research here and that a vaccine is still a long way away.
- Anyway you know the drill here - if you think this is THE Vaccine company then try and find a way into this stock - don't mortgage your house / have a plan and put a small % to work.
- Technically massive uptrend and probably a 2 places to get long - either at the immediate demand zone (66ish) or the 50ish. There is some negative divergence kicking in with the Connor's RSI and so a bigger dip here is possible.
- We also then saw massive buying push the market cap to now $29 billion. This is NOT a proven company and doesn't have any marketable product YET.
- Some concern has since been expressed by Vaccine experts others on on when company will release full data / research here and that a vaccine is still a long way away.
- Anyway you know the drill here - if you think this is THE Vaccine company then try and find a way into this stock - don't mortgage your house / have a plan and put a small % to work.
- Technically massive uptrend and probably a 2 places to get long - either at the immediate demand zone (66ish) or the 50ish. There is some negative divergence kicking in with the Connor's RSI and so a bigger dip here is possible.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.